Back to top

messenger-rna: Archive

Zacks Equity Research

U.S. Govt to Urge Citizens to Get New COVID-19 Shots

Shares of COVID-19 vaccine makers soared after reports suggest that the Biden administration will start a campaign urging citizens to vaccinate themselves with updated shots vaccine in the upcoming fall.

PFENegative Net Change MRNANegative Net Change NVAXPositive Net Change BNTXNegative Net Change

Zacks Equity Research

Moderna (MRNA) Updated COVID Jab Effective Against Eris Variant

Moderna's (MRNA) updated monovalent COVID-19 vaccine generates a robust immune response against the dominating Eris variant and another rapidly spreading virus strain in a clinical study.

PFENegative Net Change MRNANegative Net Change NVAXPositive Net Change BNTXNegative Net Change

Zacks Equity Research

Can Moderna (MRNA) Diversify Beyond Its COVID-19 Jab Sales?

With COVID-19 vaccine sales declining, Moderna (MRNA) is accelerating the development of its non-COVID pipeline. It is gearing up for potential product launches over the next three years.

PFENegative Net Change MRKPositive Net Change MRNANegative Net Change BNTXNegative Net Change

Sundeep Ganoria

4 Biotech Stocks Set to Outpace Q2 Earnings Estimates

Let us look at some biotech stocks, ARCT, AXSM, EBS and NVAX, which are poised to beat on second-quarter earnings.

NVAXPositive Net Change ARCTPositive Net Change EBSPositive Net Change AXSMNegative Net Change

Zacks Equity Research

Moderna (MRNA) Beats on Q2 Earnings & Sales, Raises '23 View

Moderna (MRNA) beats expectations for earnings and sales. Management raises its product revenue guidance based on potential U.S. demand for COVID vaccines during the upcoming fall season.

JNJPositive Net Change MRKPositive Net Change MRNANegative Net Change CRBUPositive Net Change

Zacks Equity Research

Moderna (MRNA) to Report Q2 Earnings: Will It Beat Estimates?

Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates when it reports second-quarter earnings.

NVOPositive Net Change MRKPositive Net Change MRNANegative Net Change ACADNegative Net Change

Zacks Equity Research

Moderna (MRNA) Initiates Rolling BLA Filing for RSV Vaccine

Alongside the FDA filing, Moderna (MRNA) submits similar filings in Europe and Australia, seeking approval for using its RSV vaccine in older adults aged 60 years and above.

AZNPositive Net Change GSKPositive Net Change PFENegative Net Change MRNANegative Net Change